Literature DB >> 8256750

Rate-corrected QT interval: techniques and limitations.

C Funck-Brentano1, P Jaillon.   

Abstract

The duration of the QT interval on the surface electrocardiogram represents the time required for all ventricular depolarization and repolarization processes to occur. Among the many physiologic and pathologic factors that contribute to the QT interval, heart rate plays a major role. Several approaches have been used to correct the QT interval, all of which take into account the heart rate at which the interval is measured. The simplest and most common approach to correcting the QT interval is to divide its value by the square root of the preceding RR interval expressed in seconds, i.e., by using Bazett's formula. This calculation provides a corrected QT (QTc) interval that represents the QT interval normalized for a heart rate of 60 beats/min. However, several studies have shown that Bazett's correction formula is not optimal. Fridericia's cube-root formula has been shown to perform better in correcting the QT interval for heart rate. Other formulas require the measurement of several QT-RR pairs at various heart rates to obtain a reliable QTc interval and are therefore not easily usable. Any correction formula is likely to introduce an error in assessing the QTc interval. Although the importance of this error should not be minimized, the corrected QT interval remains useful in assessing the effects of drugs on the duration of repolarization. For this purpose, Fridericia's cube-root formula is preferable to Bazett's square-root formula.(ABSTRACT TRUNCATED AT 250 WORDS)

Mesh:

Year:  1993        PMID: 8256750     DOI: 10.1016/0002-9149(93)90035-b

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  72 in total

Review 1.  Assessing the cardiac safety of ebastine. Epilogue.

Authors:  D J Roberts
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Relationship between resting electrocardiographic parameters and estimated 10-year risk for coronary heart disease in healthy adults in the USA.

Authors:  Jong-Min Lee; Ki-Dong Yoo; Yong-Seog Oh; Dong-Bin Kim; Chan-Seok Park; Sung-Won Jang; Ji-Hoon Kim; Sang-Hyun Ihm; Hee-Yeol Kim; Man-Young Lee; Ki-Bae Seung; Tai-Ho Rho
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-10       Impact factor: 1.468

Review 3.  Cardiac effects of ebastine and other antihistamines in humans.

Authors:  A J Moss; J Morganroth
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

4.  Assessment of the stability of the individual-based correction of QT interval for heart rate.

Authors:  Jean-Philippe Couderc; Xia Xiaojuan; Wojciech Zareba; Arthur J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-01       Impact factor: 1.468

5.  Surface electrocardiography and histologic rejection following orthotopic heart transplantation.

Authors:  Robert E Eckart; Mark W Kolasa; Nancy A Khan; Michael D Kwan; Mark E Peele
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-01       Impact factor: 1.468

Review 6.  Cardiac disease and Rett syndrome.

Authors:  M Acampa; F Guideri
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

7.  ECG evaluation of ventricular properties: the importance of cardiac cycle length.

Authors:  Fabrice Extramiana; Antoine Leenhardt; Pierre Maison-Blanche
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

8.  QT dynamics early after exercise as a predictor of mortality.

Authors:  Nils P Johnson; Thomas A Holly; Jeffrey J Goldberger
Journal:  Heart Rhythm       Date:  2010-05-15       Impact factor: 6.343

9.  Limits of corrected flow time to monitor hemodynamic status in children.

Authors:  E Wodey; F Carre; X Beneux; A Schaffuser; C Ecoffey
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

10.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.